Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Good Old Days: FDA's Jenkins Instructs Reviewers To Meet Original User Fee Review Time Standard

This article was originally published in The Pink Sheet Daily

Executive Summary

Office of New Drugs Director instructs FDA reviewers to return to the practice of meeting 90 percent of their review time goals for new drug applications.

You may also be interested in...



GAO Gives FDA Drug Review Performance Seal Of Approval

FDA met most user fee performance goals for NDAs and BLAs received in fiscal years 2000 through 2010, the government watchdog agency says in a report prepared for Sens. Burr and Coburn. The legislators proposed legislation April 16 that includes a requirement for the agency to report annually on its adherence to the user fee goals.

Office Of New Drugs Reorganization Should Better Balance Workload, FDA Says

CDER's Office of New Drugs reorganizes as rheumatology moves from analgesics to join allergy.

Office Of New Drugs Reorganization Should Better Balance Workload, FDA Says

CDER's Office of New Drugs reorganizes as rheumatology moves from analgesics to join allergy.

Related Content

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel